William Wierda, MD and Nitin Jain, MD

In this episode, “On the Horizon for CLL”, William Wierda, MD and Nitin Jain, MD offer insights on the future of CLL therapy.

Among emerging therapies, a variety of next-generation targeted therapies, including new BTK inhibitors, are in late-stage development. There is also quite a lot of research activity with CAR-T cells in CLL, although challenges remain. The exciting advances in CLL are likely to continue, with significant improvements in cure rates and MRD negativity anticipated in the next 1 to 2 years.



Share this story, choose your platform!